Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study

BACKGROUND: In the PARADIGMS Study, fingolimod demonstrated superior efficacy versus interferon (IFN) β-1a and comparable overall incidence of adverse events but slightly higher rate of serious adverse events in patients with paediatric-onset multiple sclerosis (PoMS). Here, we report the health-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Krupp, Lauren, Banwell, Brenda, Chitnis, Tanuja, Deiva, Kumaran, Gaertner, Jutta, Ghezzi, Angelo, Huppke, Peter, Waubant, Emmanuelle, DeLasHeras, Virginia, Azmon, Amin, Karan, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883212/
https://www.ncbi.nlm.nih.gov/pubmed/35308898
http://dx.doi.org/10.1136/bmjno-2021-000215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883212/
https://www.ncbi.nlm.nih.gov/pubmed/35308898
http://dx.doi.org/10.1136/bmjno-2021-000215

Ejemplares similares